This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gheorghiade, M. Articles by Colucci, W. S. Search for Related Content PubMed PubMed Citation Articles by Gheorghiade, M. Articles by Colucci, W. S. Related Collections Other heart failure AHA Statements and Guidelines

(Circulation. 2006;113:2556-2564.)
© 2006 American Heart Association, Inc.

Special Report

Contemporary Use of Digoxin in the Management of Cardiovascular Disorders

Mihai Gheorghiade, MD; Dirk J. van Veldhuisen, MD, PhD; Wilson S. Colucci, MD

From the Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Ill (M.G.); University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (D.J.v.V.); and Division of Cardiology, Boston University, Boston, Mass (W.S.C.).

Correspondence to Mihai Gheorghiade, MD, Division of Cardiology, Northwestern University, Feinberg School of Medicine, Galter 10-240, 201 E Huron St, Chicago, IL 60611. E-mail m-gheorghiade@northwestern.edu

Key Words: digoxin • heart failure • atrial fibrillation

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Digoxin Use in Cardiovascular Medicine: Past and Present

 
Digitalis is the oldest compound in cardiovascular medicine that continues to be used in contemporary clinical practice.¹ Evidence supporting the beneficial effects of digoxin on hemodynamic, neurohormonal, and electrophysiological parameters has been accumulated from >200 years of clinical experience and research (Table 1).²

View this table: [in this window] [in a new window]   TABLE 1. Effects of Digoxin

Digoxin was approved for heart failure in 1998 under current regulations by the Food and Drug Administration on the basis of the Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin (PROVED), Randomized Assessment of Digoxin on Inhibitors of the Angiotensin Converting Enzyme (RADIANCE), and Digitalis Investigators Group (DIG) clinical trials.^3–5 It was also approved for the control of ventricular response rate for patients with atrial fibrillation. The most recent American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend digoxin for symptomatic chronic heart failure for patients with reduced systolic function (Class IIa recommendation: weight of evidence/opinion is in favor of usefulness/efficacy), preserved systolic function (Class IIb: usefulness/efficacy is less well established by evidence/opinion), and/or rate control for atrial fibrillation with a rapid ventricular response (Class IIa).⁶ The new Heart Failure Society of America guidelines for heart failure provide similar recommendations.⁷

Despite its relatively recent approval by the Food and Drug Administration and the guideline recommendations, digoxin use is decreasing in patients with heart failure.⁸ In the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) registry, only 30% of patients with left ventricular systolic dysfunction were being treated with digoxin before admission. Digoxin was . . . [Full Text of this Article]

This article has been cited by other articles:

				M. Gheorghiade and E. Braunwald Reconsidering the Role for Digoxin in the Management of Acute Heart Failure Syndromes JAMA, November 18, 2009; 302(19): 2146 - 2147. [Full Text] [PDF]

				F. Triposkiadis, G. Karayannis, G. Giamouzis, J. Skoularigis, G. Louridas, and J. Butler The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J. Am. Coll. Cardiol., November 3, 2009; 54(19): 1747 - 1762. [Abstract] [Full Text] [PDF]

				L. V. Fedorova, V. Raju, N. El-Okdi, A. Shidyak, D. J. Kennedy, S. Vetteth, D. R. Giovannucci, A. Y. Bagrov, O. V. Fedorova, J. I. Shapiro, et al. The cardiotonic steroid hormone marinobufagenin induces renal fibrosis: implication of epithelial-to-mesenchymal transition Am J Physiol Renal Physiol, April 1, 2009; 296(4): F922 - F934. [Abstract] [Full Text] [PDF]

				M. Gheorghiade and P. S. Pang Acute heart failure syndromes. J. Am. Coll. Cardiol., February 17, 2009; 53(7): 557 - 573. [Abstract] [Full Text] [PDF]

				M. P. Blaustein, J. Zhang, L. Chen, H. Song, H. Raina, S. P. Kinsey, M. Izuka, T. Iwamoto, M. I. Kotlikoff, J. B. Lingrel, et al. The Pump, the Exchanger, and Endogenous Ouabain: Signaling Mechanisms That Link Salt Retention to Hypertension Hypertension, February 1, 2009; 53(2): 291 - 298. [Full Text] [PDF]

				N. M. Albert Improving Medication Adherence in Chronic Cardiovascular Disease Crit. Care Nurse, October 1, 2008; 28(5): 54 - 64. [Full Text] [PDF]

				R. A. Newman, P. Yang, A. D. Pawlus, and K. I. Block Cardiac Glycosides as Novel Cancer Therapeutic Agents Mol. Interv., February 1, 2008; 8(1): 36 - 49. [Abstract] [Full Text] [PDF]

				L. Liu, X. Zhao, S. V. Pierre, and A. Askari Association of PI3K-Akt signaling pathway with digitalis-induced hypertrophy of cardiac myocytes Am J Physiol Cell Physiol, November 1, 2007; 293(5): C1489 - C1497. [Abstract] [Full Text] [PDF]

				Y.-L. He, R. Sabo, G. Sunkara, M.-N. Bizot, G.-J. Riviere, S. Leon, M. Ligueros-Saylan, W. P. Dole, and D. Howard Evaluation of Pharmacokinetic Interactions Between Vildagliptin and Digoxin in Healthy Volunteers J. Clin. Pharmacol., August 1, 2007; 47(8): 998 - 1004. [Abstract] [Full Text] [PDF]